Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jul;41(7):1444–1448. doi: 10.1128/aac.41.7.1444

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus.

S F Innaimo 1, M Seifer 1, G S Bisacchi 1, D N Standring 1, R Zahler 1, R J Colonno 1
PMCID: PMC163937  PMID: 9210663

Abstract

BMS-200475 is a novel carbocyclic 2'-deoxyguanosine analog found to possess potent and selective anti-hepatitis B virus (anti-HBV) activity. BMS-200475 is distinguished from guanosine by replacement of the natural furanose oxygen on the sugar moiety with an exo carbon-carbon double bond. In the HepG2 stably transfected cell line 2.2.15, BMS-200475 had a 50% effective concentration (EC50) of 3.75 nM against HBV, as determined by analysis of secreted HBV DNA. Structurally related compounds with adenine, iodouracil, or thymine base substitutions were significantly less potent or were inactive. Direct comparison of the antiviral activities of BMS-200475 with those of a variety of other nucleoside analogs, including lamivudine (EC50 = 116.26 nM), demonstrated the clearly superior in vitro potency of BMS-200475 in 2.2.15 cells. Intracellular HBV replicative intermediates were uniformly reduced when cells were treated with BMS-200475, but rebounded after treatment was terminated. The concentration of BMS-200475 causing 50% cytotoxicity in 2.2.15 cell cultures was 30 microM, approximately 8,000-fold greater than the concentration required to inhibit HBV replication in the same cell line. Treatment with BMS-200475 resulted in no apparent inhibitory effects on mitochondrial DNA content.

Full Text

The Full Text of this article is available as a PDF (540.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boucher C. A., Cammack N., Schipper P., Schuurman R., Rouse P., Wainberg M. A., Cameron J. M. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993 Oct;37(10):2231–2234. doi: 10.1128/aac.37.10.2231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chen C. H., Cheng Y. C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. J Biol Chem. 1989 Jul 15;264(20):11934–11937. [PubMed] [Google Scholar]
  3. Cui L., Yoon S., Schinazi R. F., Sommadossi J. P. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest. 1995 Feb;95(2):555–563. doi: 10.1172/JCI117698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davis M. G., Wilson J. E., VanDraanen N. A., Miller W. H., Freeman G. A., Daluge S. M., Boyd F. L., Aulabaugh A. E., Painter G. R., Boone L. R. DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs. Antiviral Res. 1996 May;30(2-3):133–145. doi: 10.1016/0166-3542(96)00938-2. [DOI] [PubMed] [Google Scholar]
  5. Dienstag J. L., Perrillo R. P., Schiff E. R., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995 Dec 21;333(25):1657–1661. doi: 10.1056/NEJM199512213332501. [DOI] [PubMed] [Google Scholar]
  6. Field A. K., Tuomari A. V., McGeever-Rubin B., Terry B. J., Mazina K. E., Haffey M. L., Hagen M. E., Clark J. M., Braitman A., Slusarchyk W. A. (+-)-(1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)-cyclobutyl] guanine [(+-)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses. Antiviral Res. 1990 Jan;13(1):41–52. doi: 10.1016/0166-3542(90)90043-7. [DOI] [PubMed] [Google Scholar]
  7. Ganem D., Varmus H. E. The molecular biology of the hepatitis B viruses. Annu Rev Biochem. 1987;56:651–693. doi: 10.1146/annurev.bi.56.070187.003251. [DOI] [PubMed] [Google Scholar]
  8. Grellier L., Mutimer D., Ahmed M., Brown D., Burroughs A. K., Rolles K., McMaster P., Beranek P., Kennedy F., Kibbler H. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 1996 Nov 2;348(9036):1212–1215. doi: 10.1016/s0140-6736(96)04444-3. [DOI] [PubMed] [Google Scholar]
  9. Kajino K., Jilbert A. R., Saputelli J., Aldrich C. E., Cullen J., Mason W. S. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol. 1994 Sep;68(9):5792–5803. doi: 10.1128/jvi.68.9.5792-5803.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Korba B. E., Boyd M. R. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother. 1996 May;40(5):1282–1284. doi: 10.1128/aac.40.5.1282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Korba B. E., Milman G. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res. 1991 Mar-Apr;15(3):217–228. doi: 10.1016/0166-3542(91)90068-3. [DOI] [PubMed] [Google Scholar]
  12. Lee B., Luo W. X., Suzuki S., Robins M. J., Tyrrell D. L. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob Agents Chemother. 1989 Mar;33(3):336–339. doi: 10.1128/aac.33.3.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ling R., Mutimer D., Ahmed M., Boxall E. H., Elias E., Dusheiko G. M., Harrison T. J. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 1996 Sep;24(3):711–713. doi: 10.1002/hep.510240339. [DOI] [PubMed] [Google Scholar]
  14. Luo G., Torri A., Harte W. E., Danetz S., Cianci C., Tiley L., Day S., Mullaney D., Yu K. L., Ouellet C. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol. 1997 May;71(5):4062–4070. doi: 10.1128/jvi.71.5.4062-4070.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Perrillo R. P., Schiff E. R., Davis G. L., Bodenheimer H. C., Jr, Lindsay K., Payne J., Dienstag J. L., O'Brien C., Tamburro C., Jacobson I. M. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990 Aug 2;323(5):295–301. doi: 10.1056/NEJM199008023230503. [DOI] [PubMed] [Google Scholar]
  16. Price P. M., Banerjee R., Jeffrey A. M., Acs G. The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2'-deoxyguanosine. Hepatology. 1992 Jul;16(1):8–12. doi: 10.1002/hep.1840160103. [DOI] [PubMed] [Google Scholar]
  17. Sells M. A., Chen M. L., Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1005–1009. doi: 10.1073/pnas.84.4.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Southern E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975 Nov 5;98(3):503–517. doi: 10.1016/s0022-2836(75)80083-0. [DOI] [PubMed] [Google Scholar]
  19. Suzuki S., Lee B., Luo W., Tovell D., Robins M. J., Tyrrell D. L. Inhibition of duck hepatitis B virus replication by purine 2',3'-dideoxynucleosides. Biochem Biophys Res Commun. 1988 Nov 15;156(3):1144–1151. doi: 10.1016/s0006-291x(88)80752-6. [DOI] [PubMed] [Google Scholar]
  20. Tamura K., Aotsuka T. Rapid isolation method of animal mitochondrial DNA by the alkaline lysis procedure. Biochem Genet. 1988 Dec;26(11-12):815–819. doi: 10.1007/BF02395525. [DOI] [PubMed] [Google Scholar]
  21. Tipples G. A., Ma M. M., Fischer K. P., Bain V. G., Kneteman N. M., Tyrrell D. L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996 Sep;24(3):714–717. doi: 10.1002/hep.510240340. [DOI] [PubMed] [Google Scholar]
  22. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Weislow O. S., Kiser R., Fine D. L., Bader J., Shoemaker R. H., Boyd M. R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst. 1989 Apr 19;81(8):577–586. doi: 10.1093/jnci/81.8.577. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES